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I.V. LABETALOL IN THE TREATMENT OF HYPERTENSION FOLLOWING
CORONARY-ARTERY SURGERY
D. R. MOREL, A. FORSTER AND P. M. SUTER
SUMMARY
The cardiovascular effects of incremental fixed i.v. doses of labetalol were evaluated in 10 normovolaemic
sedated patients presenting with hypertension and tachycardia in the early period after myocardial revas-
cularizaoon. A first dose of 20 mg was sufficient to provoke a «igni'fimnt (P < 0.01) mean decrease in systolic
(-9.3%), diastolic (-8.2%) and mean arterial (-7.9%) pressure (AP) and in the rate-pressure product
(RPP) (-13.1%). The mean heart rate (HR) did not change significantly, but a linear correlation could be
established between the change at 2 min and the value before injection (r = 0.73). A second dose of labetalol
40 mg given S min later did not decrease AP further, but a significant decrease in HR was noted. A marked
difference in the individual response among patients was found as the range of effective total doses per kg
body weight was 0.6-4.1 mgkg"1 (mean 2.2). Apart from one patient, no patient needed vagolytic or
sympathomimetic drugs to oppose the alpha or beta actions of labetalol during the 24-h follow-up period.
The occurrence of hypertension and tachycardia
after myocardial revascularization has been ob-
served in 30-60% of patients undergoing coronary
artery surgery (Estafanous et al., 1973; Hoar, Hick-
ey and Ullyot, 1976; Roberts et al., 1977; Fouad,
Estafanous and Tarazi, 1978). This syndrome ap-
pears usually within the first 2 h after the patient has
returned to the intensive care unit (ICU) and lasts
about 4-8 h. It can lead to various and severe com-
plications, including haemorrhage, arrhythmia,
myocardial ischaemia or infarction. Several treat-
ments have been proposed, including vasodilator
therapy (Estafanous et al., 1973; Roberts et al.,
1977; Fouad, Estafanous and Tarazi, 1978), ex-
tradural anaesthesia (Hoar, Hickey and Ullyot,
1976), preoperative stellate ganglion blockade (Bid-
wai et al., 1979). Beta-adrenergic blocking agents
seem less successful; i.v. propranolol was shown to
increase total peripheral resistance, partly in re-
sponse to the reduction of cardiac output and also
possibly because of unopposed alpha stimulation
(Ulrychetal.,1%8).
Labetalol is a drug which competitively blocks
both alpha- and beta-adrenoceptors (Farmer et
al., 1972; Brittain and Levy, 1976), and which has
an elimination plasma half-life of 4.0 i 0.5 h in man
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(Martin, Hopkins and Bland, 1976). It has the
advantage over pure vasodilators of counteracting
the baroreceptor reflex increase in HR and cardiac
output elicited by the AP decrease. On the other
hand, its alpha-adrenoceptor blocking property de-
creases left ventricular fining pressure, which can be
increased by the use of pure beta-adrenoceptor an-
tagonists (Peter et al., 1978). These unique phar-
macological properties make labetalol particularly
attractive as an antihypertensive agent, especially in
patients suffering from coronary artery disease in
whom the aim is to reduce myocardial oxygen con-
sumption. As the latter can be estimated from the
rate-pressure product (RPP) (Gobel et al., 1978),
labetalol, acting on both components of this pro-
duct, will improve angina pectoris by Himinishing
myocardial oxygen consumption.
The purpose of this study was to evaluate the
cardiovascular effects of incremental fixed i.v. doses
of labetalol in patients presenting with hypertension
and tachycardia in the early period following
myocardial revascularization.
PATIENTS AND METHODS
The study was approved by the Committee on
Human Research of our institution.
Patients
The study was begun in the ICU, during the first
2 h after operation in 10 patients who presented with
hypertension and tachycardia, as defined below,
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TABLE I. Patients studied and haemodynamk data before operation
(n = 10). AP- arterial pressure; RPP — rate-pressure product;
LVEDP" Left ventricular end-dtastolic pressure (catheterism
laboratory data)
Age(yr)
Weight (kg)
Systolic AP (kPa)
Diastolic AP (kPa)
Heart rate (beat min"1)
RPP(kPamin-1)
LVEDP(kPa)
Ejection fraction (%)
Mean±SD
57±9
81±9
20±3
1211.6
72±8
1423 ±200
2.5±0.8
57 ±12
Range
45-71
69-95
18-25
11-15
55-80
1100-1727
1.6-3.7
30-70
after an elective aortocoronary bypass operation.
The clinical data are reported in table I. All patients
were males and coronary artery disease had been
recognized clinically and confirmed before opera-
tion with coronary arteriography. All but one pa-
tient were receiving adequate beta-blocker treat-
ment (oxprenolol or pindolol), but did not receive a
beta-blocker the day of surgery, and three patients
were known to be hypertensive before operation.
Anaesthesia and postoperative management
The anaesthetic technique and the postoperative
management were identical in all patients. Anaes-
thesia was induced with flunitrazepam 0.03 mgkg"1
and pancuronium bromide O.lmgkg"1 and main-
tained with 40% oxygen in 60% nitrous oxide and
fentanyl (total dose 1.0-1.5 ing) and droperidol
10-15 mg. Recovery from cardiopulmonary bypass
was achieved without difficulty in all patients and no
vasopressor agent was used after coronary bypass.
The tracheal tube was kept in place and the lungs
artificially ventilated for the first 12 h after operation
to maintain arterial PCO2 between 4.6-5.3kPa and
arterial PO2 greater than 16kPa. The electrocardio-
gram and AP were monitored continuously. Cen-
tral venous pressure (c.v.p.), urine output and
blood loss from the chest drains were recorded and
all losses adequately replaced. Serum electrolytes
and haematocrit were measured regularly and any
abnormality corrected. The patients were sedated
with small doses of morphine (mean dose±SD)
5.3±2.8mg, diazepam 8.5±5.2mg and chlor-
promazine 5.0±2.6mg i.v. over the first 4h after
operation.
A hypertension and tachycardia syndrome was
defined as a sustained increase of RPP of more than
665 kPamin"1 greater than the patient's preopera-
tive value, which ranged between 1100 and 1720,
with systolic AP remaining greater than 16kPa,
excluding hypoxia, hypercarbia, shivering, fighting
the ventilator or intolerance of the endotracheal
tube, and which could not be reversed with simple
sedation. The patients were admitted to the labetalol
study if they maintained a hypertension and
tachycardia syndrome for at least 30 min in spite of
proper sedation and analgesia, as judged clinically.
Once the patient was in the study, the following
variables were measured and recorded continuously
on a four-channel polygraph: e.c.g. and HR by
precordial derivation, systolic, diastolic and mean
arterial pressure through a radial artery catheter and
c.v.p. through a venous catheter with the zero refer-
ence point situated at mid-axillary level. RPP was
calculated from the product of systolic AP x HR.
The recording of the data was continued for 30 min,
then the haemodynamic variables were noted every
hour for a 24-h follow-up period. Secondary effects
of labetalol and the need for vasoactive drugs were
also recorded.
Labetalol was administered i.v. through a vein in
the forearm over 15 s. First all patients were given a
20-mg dose. After 5 min, 40mg was injected if
hypertension and tachycardia were still present.
Five minutes later, the patients who were still pres-
enting with the syndrome received 80 mg of
labetalol and this dose again every 5 min if indicated,
until a total dose of labetalol 300 mg was achieved.
Statistical analyses
A Student's paired t test was used for statistical
evaluation. The results are presented as means ± one
standard deviation of the mean (x± SD).
RESULTS
The time courses of changes in arterial pressure, HR
and the RPP are reported in figure 1. The first dose
of labetalol 20 mg was sufficient to provoke a sig-
nificant (P<0.01) mean decrease in systolic
(-9.3%), diastolic (-8.2%) and mean arterial
(-7.9%) pressure and in RPP (-13.1%). Mean HR
did not change significantly, but a linear correlation
could be established between change at 2 min and
the value before injection (fig. 2; r = -0.73). A simi-
lar correlation could be established between the
change in systolic AP after 1 min and the value
before injection: r= -0.62, P<0.05 (fig. 3).
The second dose of labetolol given 5 min later did
not decrease AP further, but a significant decrease
in HR was noted. Eight of 10 patients required a
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FIG 1. Haemodynamic effects of labetalol (mean ± SD, n = 10) given by incremental l.v bolus injection
*.P<0.05, **P<0.01. Arterial pressures: O = systolic, • = mean, • = diastohc.
third injection at lOmin and its haemodynamic
effect was statistically significant. Three patients
continued to manifest the hypertension and
tachycardia syndrome after a total dose of 140 mg,
but responded after two additional doses, each of
80 mg of labetalol. Thus there was a marked differ-
ence in the individual response among patients: the
range of total doses per kg body weight was
0.6-4.1 mg kg"1 (mean 2.2) and there was no corre-
lation between the need for labetalol and clinical and
haemodynamic data before operation.
If the three "resistant" patients, who needed up
to 300 mg of labetalol to attenuate their hyperten-
sion and tachycardia syndrome were excluded from
the study, then the remainder, who received a mean
dose of labetalol 1.46±0.56mgkg~1, had a signific-
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FIG. 2. Linear correlation between the decrease in heart rate
during the first 2 min (A HR0-2) after labetalol injection and its
control value.
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FIG . 3. Linear correlation between the decrease insystolicartenal
pressure during the 1st min (A SAP 0-1) after labetalol injection
and its control value
ant ( P < 0.005) percentage decrease in their
haemodynamic variables of 11% (systolic), 10%
(diastolic), 10% (mean AP) and 18% (RPP). In these
patients, the correlation between the change in sys-
tolic AP after 1 min v. the value before infection was
r = 0.91 ( P < 0.005).
During the following hours AP continued to de-
crease spontaneously, even to values less than those
before operation, with a smallest value almost al-
ways at 12 h after the start of the study, at which
time the HR was also slowest. Twenty-four hours
after the beginning of the investigation, AP values
were about the same as those occurring before oper-
ation, while there persisted a relative faster HR
(89 beat min-1)-
During the whole period of investigation, c.v.p.
remained stable, with a mean value of 7 ± 4 cm H2O
before injection and ranging from 7±4tolO±3cm
H2O after labetalol. Rectal temperature at the begin-
ning of the study was 36±0.4°C and regularly
increased to 38.5±0.3°C 6h later and to
38.1±0.3°Cat24h.
Apart from the haemodynamic changes produced
by labetalol, we observed a reduction of ventricular
extrasystolic beats in three patients. In one patient,
unifocal ectopic ventricular beats appeared after the
first 80-mg dose, lasting for 15 min. Another
patient, the oldest of the group (71 yr), and who had
the greatest left ventricular end-diastolic pressure
value before operation (3.7kPa) and the worst ejec-
tion fraction (30%), suddenly presented multifocal
ventricular ectopic beats followed by bradycardia
and ventricular fibrillation 90 min after the injec-
tion. After internal cardiac massage and defibrilla-
tion, the patient's heart recovered sinus rhythm for
30 min, then a similar episode occurred again and
cardiopulmonary resuscitation was unsuccessful.
The postmortem examination of the heart showed a
large fresh anterior infarct.
Apart from this patient, no subject needed
vagolytic or sympathomimetic drugs to oppose the
alpha or beta actions of labetalol during the 24-h
follow-up period, but three patients received small
doses of dopamine (3-4 fig kg"1 min"1) to improve
renal perfusion between 6 and 18 h after operation.
DISCUSSION
Hypertension after myocardial revascularization
with or without tachycardia in well ventilated and
sedated patients is mainly caused by sympathetic
hyperactivity with increased peripheral vascular re-
sistance associated with increased plasma
catecholamine concentrations (Roberts et al., 1977).
In our institution, the frequency of this syndrome,
as defined in this study, is 45% of 120 coronary
bypass operations per year, which is in accordance
with previous reports (Estafanous et al., 1973;
Hoar, Hickey and Ullyot, 1976; Roberts et al.,
1977; Fouad, Estafanous and Tarazi, 1978).
The theoretical advantage of labetalol in ant-
agonizing simultaneously both alpha- and beta-
adrenoceptor sites has been confirmed in our study.
Labetalol 20mgi.v. administered over 15 s has
proved to be efficient in diminishing RPP clinically
and statistically. The second (40 mg) and the third
doses (80 mg) produced further progressive reduc-
tions of RPP. Three of 10 subjects, none hyperten-
sive before operation, did not react to the loading
dose of 140 mg and needed up to 300 mg to decrease
RPP adequately.
An interesting feature of labetalol is the fact that
individual changes are influenced by the degree of
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resting sympathetic drive, thus more marked reduc-
tions in HR have been observed in patients with
high HR values before injection, just as a greater
decrease in systolic AP is found with high AP values
before injection.
Our starting doses (20 mg) were far less than the
dose recommended for chronically hypertensive
subjects (Pearson and Havard, 1976; Ciumming et
al., 1979), but larger than those administered by
Meretoja and others (1980) to a similar group of
patients (mean total dose 15 mg). This difference in
the sensitivity of such patients may be explained by
the different times after the end of operation at
which labetalol was given. Meretoja administered
the drug, on average, 6 h after the end of extracor-
poreal circulation, a time at which the post-
myocardial revascularization hypertension syn-
drome is frequently ceasing spontaneously, what-
ever treatment is applied. The AP of Meretoja's
patients were significantly lower (mean 13.3 kPa)
with one patient having a mean AP of lOkPa
associated with HR 59beatmkr1 before the
labetalol injection. The difference between his and
our findings is therefore not surprising: the earlier
patients needed less adrenergic antagonists than
those reported in the present study, in which
labetalol was injected after operation during the first
2 h in more severely hypertensive patients.
The relative long duration of action of labetalol,
lasting for 4-18 h (Pearson and Havard, 1976; Cum-
ming et al., 1979), may be helpful in protecting the
patient with coronary artery disease during the
hypertensive period, but its use implies a careful
monitoring of blood volume because physiological
compensatory mechanisms may be attenuated by
labetalol. It is difficult to determine if the fatal
outcome in one patient in our series was precipitated
by the use of labetalol, but it is noteworthy that this
patient had a previous history of recurrent episodes
of supraventricular tachycardia necessitating elec-
trical shock and that he was the only patient not
receiving beta-blockade treatment. Although
Chiarello and others (1980) have demonstrated a
protective effect of labetalol on myocardial cell nec-
rosis after coronary artery occlusion in rats and
studies in humans emphasized the beneficial effect
of this drug in patients with angina pectoris (Bester-
man and Spencer, 1979) or acute myocardial infarc-
tion with systemic hypertension (Marx and Reid,
1979), once the arrhythmia in this patient had occur-
red, it was probably more difficult to perform suc-
cessful cardiac resuscitation under labetalol than
under a short-acting vasodilating agent. Thus, if the
hypertension cannot be corrected by an i.v. dose of
labetalol 100-150 mg administered over lOmin,
then another mode of decreasing AP, for instance by
i.v. sodium nitroprusside, should be considered.
We conclude that i.v. labetalol administered over
15 s in incremental fixed doses starting with 20 mg
and, if necessary, doubling the dose after a 5-min
interval until a total dose of 2 mg kg"1 is achieved, is
safe and effective in producing a rapid reduction in
RPP in patients presenting an acute postmyocardial
revascularization hypertension syndrome. It would
seem from our study that, if there is no effect after a
140-mg loading dose, greater doses of labetalol have
little further beneficial action and can mask a slowly
developing cardiovascular decompensation or may
decrease the efficiency of a haemodynamio resusci-
tation.
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I.V. LABETALOL ZUR BEHANDLUNG DES
HYPERTONUS NACH OPERATION AN DEN
KORONARARTERIEN
ZUSAMMENFASSUNG
Die kardiovaskularen Wirkungen von Labetabol in einer fest-
gelegten ansteigenden l.v. Dosierung wurden an zehn normo-
volamischen, sedierten Patienten gemessen, die in der fruhen
postoperanven Phase nach der myokardialen Revaskulansierung
an Hypertonus und Tachykardie htten. Erne erste Dosis von
20 mg reichte aus, um cine significant^ durchschnirtbche Senk-
ung des systolischen (-9,3%), des diastolischen ( - 8,2%) und des
mittleren artenellen Druckes sowie des Produktes aus Frequenz
und Druck (RRP) hervorzurufen (-13,1%). Die mittlerc
Herzfrequenz indent sich nicht signifikant, aber es konnte eine
lineare Korrelaoon hergestellt werden zwischen der Veran-
derung nach 2 mm und dem Wert vor der Injektion (r= 0,73).
Eine 2. Dosis von Labetalol (40 mg), die 5 mm spater verabreicht
wurde, senkte den AD nicht weiter, aber es war ein signifikanter
Abfall der HF festzustellen. In der individuellen Ansprechbar-
keit bestand ein grofler Unterschied zwischen den Patienten, da
der Bereich der wirksamen Gesamtdosen pro kg KM von 0,6 bis
4,1 mgkg"1 (durchschnittbeh 2,2) reichte. Aussereinem Pauen-
ten benotigte keiner vagolytische oder sympathomimetische
Medikamente, um Wirkungen auf alpha- oder beta-Rezeptoren
von Labetolol in den darauffolgenden 24 h entgegenzuwirken.
LE LABETALOL I.V. DANS LE TRATTEMENT
DE L'HYPERTENSION APRES CHIRURGIE
DES ARTERES CORONAIRES
RESUME
Les effets cardiovasculaires de doses croissantes pr£determinees
de labetalol out etc Studies chez 10 patients normovolemiques
ayant recu des seclatifs et presentant une hypertension et une
tachycardie dans la periode post-operatoire precoce apres une
revascularisation du myocarde. Une premiere dose de 20 mg £tait
tuf fisante pour induire une diminution moyenne significative
( P < 0,01) des pressions arterielles systohques ( - 9,3%), diastoli-
que (— 8,2%) et moyenne ( - 7,9%) et du produit pression frequ-
ence (PPF) (-13,1%). La frequence cardiaque moyenne (FC)
n'etait pas significativement modifiee mais une correlation
lineaire pouvait etre etablie entre les modifications a 2 min et la
valeur avant l'injection (r - 0,73). Une deujrieme dose de labetalol
(40 mg) administree 5 min plus tard n'entrainait pas de diminu-
tion significative de la FC. La reponse individuelle vanait
beaucoup selon les patients et la gnmmi* de doses totales efficaces
park kg de poids corporel allait de 0,6 a 4,1 rngkg"' (moyenne
2,2). A 1'exception d'un patient, aucun sujet n'a eu besoin de
vagolytiques ou de sympathomimetiques pour antagoniser les
actions alpha ou beta de labetalol pendant les 24h de la periode
d'etude.
LABETALOL I.M. EN EL TRATAMffiNTO DE LA
HIPERTENSION DESPUES DE CIRUjlA DE LA
ARTERIA CORONARIA
SUMARIO
Se procedio a la evaluation de los efectos cardiovasculares de dosis
i.v. crecientes fijas de labetalol administradas a 10 pacientes
normovolemicos reposados que padecian de hipertension y ta-
quicardia en el periodo inmediato despues de una revasculariza-
cion miocardiaca. Bast6 con una primera dosis de 20 mg para
provocar un descenso medio significante ( P < 0,01) de la presion
(AP) arterial media (-7,9%), sistolica (-9,3%) y diastdlica
(-8,2%) asi como el producto presion-ritmo (RPP) (-13,1%).
El ritmo cardiaco medio (HR) no cambio de manera significante,
pero pudo establecerse una correlacion linear entre el cambio a los
2 min y el valor antes de la inyecci6n(r = 0,73). Una segunda dosis
de labetalol de 40 mg administrada 5 min despues no hizo bajar
mas la AP, pero se observe una disminucion significativa del HR.
Se not6 una diferencu marcada en la respuesta individual entre
los pacientes segun variaba la gama de dosis totales efectivas por
kg de peso corporal de 0,6 a 4,1 ing kg"1 (promedio 2,2). Salvo un
solo paciente, ningun otro necesito substandas vagoliticas o
simpatomimeticas que se opusieran a las acciones alfa o beta del
labetalol durante el periodo siguiente de 24 h.
